Your session is about to expire
← Back to Search
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Phase 2
Waitlist Available
Research Sponsored by Navidea Biopharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 39 days
Awards & highlights
No Placebo-Only Group
Summary
This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
Eligible Conditions
- Rheumatoid Arthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 39 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 39 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Normal Limits of TUVjoint in Healthy Subjects
Qualitative Evaluation of SPECT/CT for Tilmanocept Localization
Secondary study objectives
Normal Distribution of TUVjoint
Planar and SPECT/CT Comparison
Quantitative Evaluation of SPECT/CT
Side effects data
From 2019 Phase 2 trial • 24 Patients • NCT0250959817%
Nausea
13%
Vomiting
9%
febrile neutropenia
4%
Anaemia
4%
hypokalaemia
4%
acute kidney injury
4%
pyrexia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tc99m Tilmanocept and Vital Blue Dye (Optional)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Subjects Free of Inflammatory DiseaseExperimental Treatment1 Intervention
The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
Group II: Healthy Controls and RA Subjects on Stable TherapyExperimental Treatment1 Intervention
The second arm is comprised of \[1\] disease-free HCs and \[2\] clinically diagnosed RA subjects on stable treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tc99m tilmanocept
2015
Completed Phase 2
~30
Find a Location
Who is running the clinical trial?
Navidea BiopharmaceuticalsLead Sponsor
20 Previous Clinical Trials
1,401 Total Patients Enrolled
4 Trials studying Rheumatoid Arthritis
353 Patients Enrolled for Rheumatoid Arthritis
Michael Blue, MDStudy DirectorNavidea Biopharmaceuticals
9 Previous Clinical Trials
415 Total Patients Enrolled
4 Trials studying Rheumatoid Arthritis
353 Patients Enrolled for Rheumatoid Arthritis